Status:

COMPLETED

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Lead Sponsor:

Rockwell Medical Technologies, Inc.

Conditions:

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This study will investigate the administration of Triferic AVNU intravenously by three different administration schedules compared to continuous infusion over 3 hours

Detailed Description

An open-label, randomized, four period sequential study of Triferic AVNU administered intravenously by three different administration schedules compared to continuous infusion over 3 hours

Eligibility Criteria

Inclusion

  • Adult hemodialysis patients ≥18 years of age.
  • Signed informed consent to participate in the study.
  • Stable on hemodialysis prescription for ≥3 months.
  • Able to sustain hemodialysis 3x/week for 3 to 4 hours.
  • Hemoglobin concentration \>9.5 g/dL.
  • Serum TSAT ≥20%.
  • Receiving hemodialysis via AV fistula or graft.
  • Able to receive hemodialysis for 4 hours at each session over the duration of the treatment periods.
  • Able to receive intermittent heparin administration for anticoagulation of the dialysis circuit.
  • Serum TIBC ≥ 150 µg/dL.

Exclusion

  • Active bleeding disorder (GI, skin, nasal…)
  • Receiving hemodialysis via catheter.
  • Receiving IV iron within 10 days of the first on-study hemodialysis treatment.
  • Receiving oral iron within 10 days of the first on-study hemodialysis treatment.
  • Any other condition, that in the opinion of the investigator would not allow completion of the 4 hemodialysis treatments in the study.

Key Trial Info

Start Date :

June 25 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 2 2021

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT04409132

Start Date

June 25 2020

End Date

April 2 2021

Last Update

July 13 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Orlando Clinical Research Center

Orlando, Florida, United States, 32809